ReviewNature reviews. Drug discovery2023
Disease modification in inflammatory skin disorders: opportunities and challenges.
Review in Nature reviews. Drug discovery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 82 citations in OpenAlex.
- Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities.Advances in therapy · 2024Trial
- Long-Term Disease Control During Continuous Treatment with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis: a Real-World Monocentric Retrospective Study.Dermatology and therapy · 2026Article
- Development and optimization of 6-Hydroxyflavone-loaded nanoemulgel for enhanced topical anti-inflammatory activity.Inflammopharmacology · 2026Article
- Atopic Dermatitis: New Targets and Emerging Systemic Therapies.American journal of clinical dermatology · 2026Review
- Defining the Potential for Disease Modification in Atopic Dermatitis.American journal of clinical dermatology · 2026Review
- The era of advanced therapeutics for pediatric atopic dermatitis - can early systemic intervention reduce the type 2 inflammatory response and modify the atopic march?Current opinion in pediatrics · 2026Review
- From Sprinters to Marathoners: Rethinking Therapeutic Speed and Disease Modification in Atopic Dermatitis.Allergy · 2026Article
- Atopic Dermatitis Across the Lifespan: Understanding, Measuring and Minimizing Cumulative Life Course Impairment.Acta dermato-venereologica · 2026Article
- Atopic dermatitis.Nature reviews. Disease primers · 2026Review
- Plant-derived indole alkaloids in chronic inflammatory diseases: molecular mechanisms, therapeutic potential and translational challenges.Inflammopharmacology · 2026Review
- Sulforaphane in Cutaneous Disorders and Skin Injury: Mechanisms, Evidence, and Clinical Perspectives.Nutrients · 2026Review
- Plant Extracts Downregulating the JAK/STAT Signaling Pathway as a Potential Tool for Psoriasis Management: A Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Polymeric Nanogels for Skin Applications.Gels (Basel, Switzerland) · 2026Review
- Hidden immune memory niches in inflammatory skin diseases.bioRxiv : the preprint server for biology · 2026Article
- Stratum Corneum Ceramide Abnormalities in Atopic Dermatitis: Pathophysiology and Implications for Disease Management.The Journal of dermatology · 2026Review
- Assessing T-Cell Profile Shifts through IL-23 Inhibition by Guselkumab on Psoriasis.JID innovations : skin science from molecules to population health · 2026Article
- Treatment Preferences Among Systemic Therapy-Naïve Patients with Atopic Dermatitis or Psoriasis in Germany: A Multicentre Study.Dermatology and therapy · 2026Article
- Review
- Efficacy of Lebrikizumab on Pruritus: A Narrative Review.Advances in therapy · 2026Review
- From static pathology to dynamic immunity: immunological plasticity and histopathological remodeling in atopic dermatitis and psoriasis.Frontiers in immunology · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
1 author at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progress in understanding of the mechanisms underlying chronic inflammatory skin disorders, such as atopic dermatitis and psoriasis vulgaris, has led to new treatment options with the primary goal of alleviating symptoms. In addition, this knowledge has the potential to inform on new strategies aimed at inducing deep and therapy-free remission, that is, disease modification, potentially impacting on associated comorbidities. However, to reach this goal, key areas require further exploration, including the definitions of disease modification and disease activity index, further understanding of disease mechanisms and systemic spillover effects, potential windows of opportunity, biomarkers for patient stratification and successful intervention, as well as appropriate study design. This Perspective article assesses the opportunities and challenges in the discovery and development of disease-modifying therapies for chronic inflammatory skin disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.